Pharmaceutical News

RSS

ULURU presents clinical posters; highlights efficacy of Altrazeal dressing for wound care

ULURU Inc. (NYSE Alternext: ULU) today announced that Gregory Bohn, M.D., FACS, Medical Director, Trinity Wound Care and Hyperbaric Medicine, Bettendorf, Iowa, has presented nine clinical posters at the 24th Annual "Clinical Symposium on Advances in Skin and Wound Care" being held in San Antonio, Texas.

24 Oct 2009

Lpath to present clinical results of iSONEP drug in wet-AMD patients

Lpath, Inc. (OTCBB: LPTN), the category leader in therapeutic agents against bioactive lipids, will present at the 2009 BIOCOM Investor Conference, which will be held October 26-27, 2009 at the Hyatt Regency La Jolla in San Diego, California.

24 Oct 2009

FDA issues emergency use authorization for peramivir anti-viral drug

BioCryst Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA), in response to a request from the U.S. Centers for Disease Control and Prevention (CDC), has issued an emergency use authorization (EUA) for the investigational anti-viral drug intravenous (i.v.) peramivir in certain adult and pediatric patients with confirmed or suspected 2009 H1N1 influenza infection who are admitted to a hospital.

24 Oct 2009

CHMP grants positive opinion to extend the use of Angiox to patients undergoing PCI

The Medicines Company announced today that the Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion applicable to all Member States of the European Union/European Economic Area that will extend the use of Angiox (bivalirudin) to include patients with heart attacks (so-called ST segment elevation myocardial infarction (STEMI)) undergoing emergency heart procedures called primary percutaneous coronary intervention (PCI).

24 Oct 2009

African American seniors less likely to be vaccinated against flu; fear and misinformation pose problems

A study about why African American seniors do or do not get influenza vaccinations finds that many of them do not have accurate and complete information about the flu itself, the safety and efficacy of the inoculations, and the ease and necessity of getting the shots.

24 Oct 2009

Pregnant women unsure about getting H1N1 flu shot, shows new survey

Despite majorities expressing concern about getting the novel H1N1 (or swine) flu this year, only about one in four pregnant women or new mothers plan to get the H1N1 flu shot, according to findings from a new survey conducted on behalf of HealthyWomen by Harris Interactive.

24 Oct 2009

Potentia Pharmaceuticals and Alcon Research sign license and purchase option agreements

Potentia Pharmaceuticals, a privately-held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), announced today that it has entered into licensing and purchase option agreements with Alcon Research, Ltd., a wholly-owned subsidiary of Alcon, Inc.

24 Oct 2009

Human clinical trials of TissuGlu to commence in Germany

Cohera Medical, Inc. announced today that it has received approval to begin human clinical trials of its lead product TissuGlu® in Germany. Receipt of the approval allows Cohera Medical to proceed with patient recruitment and initiation of an investigational study of the company's novel internal surgical adhesive being developed for its first intended use to adhere surgical tissues together in large flap surgeries.

24 Oct 2009

MPI Research to assist Kineta in autoimmune drug development program

MPI Research, a preclinical Contract Research Organization (CRO), announced that it will be collaborating with Kineta, Inc, a Seattle-based privately held biotechnology company specializing in clinical advancement of drugs that modulate and enhance the human immune system.

24 Oct 2009

FDA issues emergency use authorization for intravenous antiviral drug peramivir in H1N1 patients

The U.S. Food and Drug Administration announced today that, in response to a request from the U.S. Centers for Disease Control and Prevention, it has issued an emergency use authorization (EUA) for the investigational antiviral drug peramivir intravenous (IV) in certain adult and pediatric patients with confirmed or suspected 2009 H1N1 influenza infection who are admitted to a hospital.

24 Oct 2009

TransMolecular announces final results from its Phase 2 clinical study of 131I-TM601

TransMolecular, Inc., a developer of innovative oncology drugs through targeted delivery technologies, today announced final results from its Phase 2 clinical study comparing the toxicity and overall survival of three versus six intracavitary injections of its anti-cancer compound 131I-TM601 in the treatment of recurrent malignant glioma.

24 Oct 2009

Media examines U.S., Mexico H1N1 vaccine campaigns, health effects of handwashing in Bolivia

The Washington Post examines H1N1 vaccine supplies across the U.S.: "With only a fraction of the tens of millions of doses of vaccine that authorities predicted would be available arriving in states, cities and towns, public health officials who spent months planning for a massive immunization program are instead scrambling to parcel out their limited supply of nasal sprays and shots," the newspaper writes.

24 Oct 2009

Nutri5, an effective natural product for the relief of menopausal symptoms

Earlier this year, the BBC reported that "HRT - Hormone Replacement Therapy - can shrink women's brains"1, after a study was published which showed that brain volume in women taking HRT was smaller in two key areas involved in thinking and memory.

23 Oct 2009

EFPIA launches a pilot project against counterfeit prescription medicines in Europe

This incidence of counterfeit prescription medicines in Europe's traditional supply chain is growing. This is why EFPIA (European Federation of Pharmaceutical Industries and Associations) has launched a pilot project that includes the testing of a coding and identification solution in Sweden.

23 Oct 2009

Vaccine Vial Monitors to monitor potential heat damage of H1N1 vaccines donated to WHO

Temptime Corporation announced today that it will donate its Vaccine Vial Monitors (VVMs) to the World Health Organization (WHO) to monitor potential heat damage of H1N1 vaccines to be distributed by WHO to developing countries most in need.

23 Oct 2009

Shire announces new pharmacokinetic data of ADHD medication

Shire plc, the global specialty biopharmaceutical company, announced new data about the pharmacokinetics of its Attention-Deficit/Hyperactivity Disorder (ADHD) medication, Vyvanse- (lisdexamfetamine dimesylate) Capsules CII, which showed that Vyvanse provided similar concentrations of its active medication in the blood when administered either intranasally or when administered orally.

23 Oct 2009

Boehringer Ingelheim receives European CHMP positive opinion for MICARDIS

Boehringer Ingelheim announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency (EMEA) has issued a positive opinion for the approval of MICARDIS® (telmisartan) for the reduction of cardiovascular morbidity.

23 Oct 2009

Archexin has potential to target and treat multiple life-threatening cancers, finds new study

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced the results of an animal study that further demonstrates the company’s Phase II oncology drug, Archexin™, as having the potential to target and treat multiple life-threatening cancers.

23 Oct 2009

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals start Phase 3 trial to evaluate Nexavar tablets

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced the companies have begun enrolling patients in an international Phase 3 trial to evaluate Nexavar® (sorafenib) tablets for the treatment of patients with radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer.

23 Oct 2009

Decision Resources predicts TNF-alpha inhibitors to dominate rheumatoid arthritis treatment

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that tumor necrosis factor (TNF)-alpha inhibitors will continue to dominate first- and second-line biologic therapy for the treatment of rheumatoid arthritis in the United States through 2011, but the more established branded drugs such as, Centocor Ortho Biotech's Remicade, Abbott's Humira and Amgen/Wyeth's Enbrel, in this class will face competition from newer entrants.

23 Oct 2009

Pharmaceutical News

ULURU presents clinical posters; highlights efficacy of Altrazeal dressing for wound care

Lpath to present clinical results of iSONEP drug in wet-AMD patients

FDA issues emergency use authorization for peramivir anti-viral drug

CHMP grants positive opinion to extend the use of Angiox to patients undergoing PCI

African American seniors less likely to be vaccinated against flu; fear and misinformation pose problems

Pregnant women unsure about getting H1N1 flu shot, shows new survey

Potentia Pharmaceuticals and Alcon Research sign license and purchase option agreements

Human clinical trials of TissuGlu to commence in Germany

MPI Research to assist Kineta in autoimmune drug development program

FDA issues emergency use authorization for intravenous antiviral drug peramivir in H1N1 patients

TransMolecular announces final results from its Phase 2 clinical study of 131I-TM601

Media examines U.S., Mexico H1N1 vaccine campaigns, health effects of handwashing in Bolivia

Nutri5, an effective natural product for the relief of menopausal symptoms

EFPIA launches a pilot project against counterfeit prescription medicines in Europe

Vaccine Vial Monitors to monitor potential heat damage of H1N1 vaccines donated to WHO

Shire announces new pharmacokinetic data of ADHD medication

Boehringer Ingelheim receives European CHMP positive opinion for MICARDIS

Archexin has potential to target and treat multiple life-threatening cancers, finds new study

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals start Phase 3 trial to evaluate Nexavar tablets

Decision Resources predicts TNF-alpha inhibitors to dominate rheumatoid arthritis treatment

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News